<DOC>
	<DOC>NCT02506179</DOC>
	<brief_summary>To evaluate the real-life effect of adalimumab on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients</brief_summary>
	<brief_title>Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient must voluntarily sign and date a patient authorization. Patient must be ≥ 18 years of age. Patient must have confirmed diagnosis of UC. Patient must have: a) moderate to severe UC (a Mayo endoscopic sub score of 2 or 3) from endoscopic investigation in the previous 3months that is closest to the baseline visit or b) a Mayo rectal bleeding subscore ≥ 2 and a calprotectine value greater than 250 µg/gr. Patient must have been previously treated with conventional therapy including corticosteroids, azathioprine and/or 6mercaptopurine (6MP), and who have had an inadequate response to or who are intolerant to such therapies. Patient must have been prescribed adalimumab as part of his treatment by his treating physician. Patient has previously received adalimumab or another anti tumor necrosis factor alpha (TNFα) or biologic therapy, including but not limited to Remicade (infliximab), Simponi (golimumab), Tysabri (natalizumab), Entyvio (vedolizumab). Patient with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery. Patient with a current diagnosis of indeterminate colitis, ulcerative proctitis only, or with a current diagnosis and/or have a history of Crohn's disease. Patient with other tumor necrosis factor (TNF) immunemodulated disease. Patient has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study. A female patient is pregnant or breastfeeding. Patient is currently participating in another prospective study including controlled clinical trials and observational studies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Moderate to severe ulcerative colitis (UC)</keyword>
	<keyword>Real-life effect</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Ulcerative colitis (UC)</keyword>
	<keyword>Patient reported outcomes (PRO)</keyword>
</DOC>